Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

Juric, Dejan; Jankú, Filip; Rodón, Jordi; A. Burris, Howard; A. Mayer, Ingrid; Schüler, Martin; Seggewiß-Bernhardt, Ruth; Gil-Martín, Marta; R. Middleton, Mark; Baselga, José; Bootle, Douglas; Demanse, David; Blumenstein, Lars; Schumacher, Karl; Huang, Alan; Quadt, Cornelia; S. Rugo, Hope

doi:10.1001/jamaoncol.2018.4475

Public

Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

Published in JAMA Oncology • Dec 13, 2018

Authors:

Dejan Juric

Filip Jankú

Jordi Rodón

Abstract

Importance: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in patients with estrogen receptor-positive (ER+), endocrine therapy-resistant breast cancers. Objective: To assess the maximum tolerated dose (MTD), safety, and activity of alpelisib, an oral, PI3Kα-specific inhibi...

Subject

Fulvestrant

Medicine

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!